

Bradley C and El-Haschimi K (2006) Detailed analysis of treatment satisfaction with oral agents plus either basal insulin glargine or mealtime analogue insulin in patients with Type 2 diabetes – the APOLLO study. *Diabetic Medicine* **23** (Suppl 4) 360 P1009.

Poster presentation at the 19th IDF World Diabetes Congress, Cape Town, 3-7th December 2006.

Clare Bradley¹, Karim El-Haschimi²

¹Royal Holloway, University of London, London, United Kingdom, ²sanofi-aventis Deutschland GmbH, Berlin, Germany

Introduction: Patients' treatment satisfaction is important in deciding between available treatments for Type 2 diabetes (T2D). We present the results of the Diabetes Treatment Satisfaction Questionnaire (DTSQ) from a 44-week, parallel, open, randomized, multinational, multicentre clinical study comparing efficacy, safety and treatment satisfaction with OADs plus either insulin glargine (LANTUS[®]) once-daily or lispro at mealtimes (3x daily) in patients with T2D poorly controlled with OADs alone (APOLLO).

Methods: The DTSQ was completed at screening, Week 20 and study endpoint (Week 44). The 8-items of the DTSQ are rated 0–6 and provide a treatment satisfaction score (maximum 36=most satisfied). Two individual items measure perceived frequency of hyperglycaemia and hypoglycaemia (maximum frequency of hyper/hypoglycaemia=6). Differences between treatment groups were evaluated using ANCOVA with treatment group, language and current OAD intake as fixed factors and baseline values as covariates.

Results: At baseline, treatment satisfaction scores were similar for the insulin glargine (25.98) and insulin lispro (26.38) groups (Table). Improvements in treatment satisfaction were seen at endpoint, and the improvement was greatest in the insulin glargine group. The change in score for perceived frequency of hyperglycaemia showed more improvement, and the score for perceived frequency of hypoglycaemia increased to a lesser extent for the glargine group.

Discussion: This study demonstrates that once-daily insulin glargine was associated with greater improvements in treatment satisfaction compared with three-times-daily insulin lispro.

	Insulin glargine (n=188)		Insulin lispro (n=191)		p
	Mean±SD	n	Mean±SD	n	
Efficacy					
<i>HbA_{1c} (%)</i>					
Baseline	8.71±0.95	174	8.64±0.95	174	
Endpoint	6.96±0.67	174	6.77±0.83	174	n/s
DTSQ parameter					
<i>Treatment satisfaction</i>					
Baseline	25.98±7.99	187	26.38±7.87	188	
Endpoint	32.21±4.55	188	29.18±6.49	191	<0.0001
<i>Perceived frequency of hyperglycaemia</i>					
Baseline	3.85±1.90	186	4.03±1.86	185	
Endpoint	1.62±1.67	188	2.13±1.77	191	0.0034
<i>Perceived frequency of hypoglycaemia</i>					
Baseline	0.96±1.57	187	1.01±1.53	186	
Endpoint	1.23±1.37	188	1.95±1.64	191	<0.0001
n/s=not significant					

This study was supported by sanofi-aventis

Word count: 297 (limit 300) (Text=224; Table=72)